Is there a cardiovascular risk associated with the use of fluoroquinolones for the treatment of osteoarticular infections? Analysis of a retrospective cohort of 817 patients from a surgical and infectious disease referral center (CRIOAC) - 12/04/25

Doi : 10.1016/j.otsr.2025.104242

Malo Buisson ^a,^b,⁎ , Philippe-Alexandre Faure ^a,^b, Barthelemy Lafon Desmurs ^b,^c, Caroline Loiez ^b,^d, Benjamin Valentin ^b,^e, Henri Migaud ^a,^b, Eric Senneville ^b,^c
^a Université Lille-Hauts de France, Service Orthopédie, Centre Hospitalier Roger Salengro, rue Emile Laine, 59000 Lille, France
^b Centre de Référence Pour le Traitement des Infections Ostéo-Articulaires Complexes (CRIOAC), Avenue du Professeur-Emile-Laine, 59037 Lille-Tourcoing, France
^c Université Lille-Hauts de France, Service Universitaire des Maladies Infectieuses et du Voyageur, Centre Hospitalier de Tourcoing 155 rue du Président Coty, 59208 Tourcoing, France
^d Université Lille-Hauts de France, Service de Microbiologie du CHU de Lille 2 avenue Oscar Lambrey, 59037 Lille, France
^e Université Lille-Hauts de France, Service de Pharmacie Clinique, Pharmacie, CHU de Lille, 59000 Lille, France

^⁎Corresponding author.

En prensa. Pruebas corregidas por el autor. Disponible en línea desde el Saturday 12 April 2025
This article has been published in an issue click here to access

Abstract

Introduction

Bone joint infection is a rare but serious complication, the treatment of which most often requires intervention combined with prolonged high-dose antibiotic therapy. Fluoroquinolones are among the standard antibiotics for the treatment of these infections, particularly in combination with rifampicin for staphylococcal infections and as monotherapy for Gram-negative bacilli infections. However, recent studies, confirmed by several meta-analyses, have highlighted an increased cardiovascular risk such as aortic aneurysm and mitro-aortic regurgitation occurring early following fluoroquinolone use, leading to recommendations for caution from health agencies. These meta-analyses are often based on limited series with numerous indication biases (variable treatment durations) and low doses. We therefore conducted a single-center, single-prescriber, real-life study of a continuous series of osteo-articular infections. The objectives were to determine the rate of cardiovascular events (aortic aneurysm, mitro-aortic regurgitation) at 60 days, the mortality rate at 60 days, and at the final follow-up.

Hypothesis

Our hypothesis was that despite long-term, high-dose treatments, there was no increased cardiovascular risk in patients treated for osteo-articular infections with fluoroquinolones.

Materials and methods

Between 2017 and 2019, 817 patients were treated at the CRIOAC (Referral Center for Complex Osteo-Articular Infections) Lille-Tourcoing (332/817 patients received treatment with fluoroquinolones). This retrospective cohort study assessed the onset or worsening of cardiovascular events (such as aortic aneurysms and mitro-aortic regurgitation) and death at 2 months using a propensity score.

Results

After propensity score weighting, there was no significant difference in the risk of aortic aneurysm and mitro-aortic regurgitation at 60 days (Odds ratio (OR) 0.921 [0.317; 2.673], p = 0.879) or in the risk of death at 60 days (OR 1.252 [0.502; 3.118]; p = 0.630). There was also no significant difference in the risk of death at last follow-up after propensity score weighting (OR 1.011 [0.646; 1.582], p = 0.962).

Discussion

The results of this study suggest that the use of fluoroquinolones in patients treated for osteoarticular infections does not pose a significant increased risk of aortic aneurysm, mitro-aortic regurgitation, or death within two months. We believe it is reasonable to continue prescribing fluoroquinolones for osteoarticular infections while maintaining surveillance for these events.